MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Ngar Yee Louie acquired 19,665 shares of MAIA Biotechnology stock in a transaction dated Thursday, April 25th. The stock was acquired at an average cost of $2.03 per share, with a total value of $39,919.95. Following the completion of the transaction, the director now directly owns 1,167,189 shares of the company's stock, valued at approximately $2,369,393.67. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
MAIA Biotechnology Stock Performance
NYSEAMERICAN MAIA opened at $2.94 on Friday. MAIA Biotechnology, Inc. has a 52-week low of $0.82 and a 52-week high of $3.07.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last released its earnings results on Thursday, March 21st. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Research analysts predict that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current year.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
